Cargando…

Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib

Proteasome inhibitors have great success for their therapeutic potential against hematologic malignancies. First generation proteasome inhibitor bortezomib induced peripheral neuropathy is considered as a limiting factor in chemotherapy and its second-generation counterpart carfilzomib is associated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jannuzzi, Ayse Tarbin, Arslan, Sema, Yilmaz, Ayse Mine, Sari, Gulce, Beklen, Hande, Méndez, Lucía, Fedorova, Maria, Arga, Kazim Yalcin, Karademir Yilmaz, Betul, Alpertunga, Buket
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115161/ https://www.ncbi.nlm.nih.gov/pubmed/32244176 http://dx.doi.org/10.1016/j.redox.2020.101502

Ejemplares similares

Proteomic approach for understanding milder neurotoxicity of Carfilzomib against Bortezomib
por: Karademir, Betul, et al.
Publicado: (2018)

Differential Interactome Based Drug Repositioning Unraveled Abacavir, Exemestane, Nortriptyline Hydrochloride, and Tolcapone as Potential Therapeutics for Colorectal Cancers
por: Beklen, Hande, et al.
Publicado: (2021)

Exploring the Anticancer Effects of Brominated Plastoquinone Analogs with Promising Cytotoxic Activity in MCF-7 Breast Cancer Cells via Cell Cycle Arrest and Oxidative Stress Induction
por: Jannuzzi, Ayse Tarbin, et al.
Publicado: (2022)

Drug Repositioning for P-Glycoprotein Mediated Co-Expression Networks in Colorectal Cancer
por: Beklen, Hande, et al.
Publicado: (2020)

Pan-cancer mapping of differential protein-protein interactions
por: Gulfidan, Gizem, et al.
Publicado: (2020)

Systems-level biomarkers identification and drug repositioning in colorectal cancer
por: Beklen, Hande, et al.
Publicado: (2021)

Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19
por: Islam, Tania, et al.
Publicado: (2020)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

In Vitro and In Silico Study to Assess Toxic Mechanisms of Hybrid Molecules of Quinone-Benzocaine as Plastoquinone Analogues in Breast Cancer Cells
por: Yilmaz Goler, Ayse Mine, et al.
Publicado: (2022)

Interactome analysis of Bag-1 isoforms reveals novel interaction partners in endoplasmic reticulum-associated degradation
por: Can, Nisan Denizce, et al.
Publicado: (2021)

Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells
por: Kawabata, S, et al.
Publicado: (2012)

Cytotoxicity of Different Nano Composite Resins on Human Gingival and Periodontal Ligament Fibroblast Cell Lines: An In Vitro Study
por: Kavuncu, Gamze, et al.
Publicado: (2020)

Tubulin binding potentially clears up Bortezomib and Carfilzomib differential neurotoxic effect
por: Malacrida, A., et al.
Publicado: (2021)

HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells
por: White, Matthew C., et al.
Publicado: (2018)

Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines
por: Takahashi, Kazuya, et al.
Publicado: (2017)

Bortezomib treatment induces a higher mortality rate in lupus model mice with a higher disease activity
por: Ikeda, Tomoko, et al.
Publicado: (2017)

Omics-Driven Biomarkers of Psoriasis: Recent Insights, Current Challenges, and Future Prospects
por: Aydin, Busra, et al.
Publicado: (2020)

Quercetin-Induced Cell Death in Human Papillary Thyroid Cancer (B-CPAP) Cells
por: Mutlu Altundağ, Ergül, et al.
Publicado: (2016)

Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib
por: Neznanov, Nickolay, et al.
Publicado: (2011)

Milder degenerative effects of Carfilzomib vs. Bortezomib in the Drosophila model: a link to clinical adverse events
por: Tsakiri, Eleni N., et al.
Publicado: (2017)

Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells
por: Lee, Min Seung, et al.
Publicado: (2021)

Polycaprolactone/Gelatin/Hyaluronic Acid Electrospun Scaffolds to Mimic Glioblastoma Extracellular Matrix
por: Unal, Semra, et al.
Publicado: (2020)

The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma
por: Besse, Lenka, et al.
Publicado: (2023)

COVID-19 patients with altered steroid hormone levels are more likely to have higher disease severity
por: Sezer, Sevilay, et al.
Publicado: (2022)

Promising Antibacterial and Antifungal Agents Based on Thiolated Vitamin K3 Analogs: Synthesis, Bioevaluation, Molecular Docking
por: Yıldırım, Hatice, et al.
Publicado: (2022)

Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
por: Ludwig, Heinz, et al.
Publicado: (2019)

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR
por: Chng, W-J, et al.
Publicado: (2017)

Bortezomib, Lenalidomide and Dexamethasone (VRd) vs Carfilzomib, Lenalidomide and Dexamethasone (KRd) as Induction Therapy in Newly Diagnosed Multiple Myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
por: Tan, Carlyn Rose, et al.
Publicado: (2023)

Proteotoxicity and Neurodegenerative Diseases
por: Ruz, Clara, et al.
Publicado: (2020)

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)
por: Yong, Kwee L., et al.
Publicado: (2021)

Higher Body Fat and Lower Fat-Free Mass in Girls with Premature Adrenarche
por: Cebeci, Ayşe Nurcan, et al.
Publicado: (2015)

Clinical and Imaging Findings in Childhood Posterior Reversible Encephalopathy Syndrome
por: GUNGOR, Serdal, et al.
Publicado: (2018)

Higher adrenomedullin levels during implantation are associated with successful pregnancy
por: Karli, Pervin, et al.
Publicado: (2020)

Proteasome inhibitors bortezomib and carfilzomib used for the treatment of multiple myeloma do not inhibit the serine protease HtrA2/Omi
por: Csizmadia, Vilmos, et al.
Publicado: (2016)

Transcriptomic profile of Pea3 family members reveal regulatory codes for axon outgrowth and neuronal connection specificity
por: Kandemir, Başak, et al.
Publicado: (2020)

Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib
por: Kastritis, E, et al.
Publicado: (2017)

Polymorphisms in Tumour Necrosis Factor Alpha (TNFα) Gene in Patients with Acute Pancreatitis
por: Özhan, Gül, et al.
Publicado: (2010)

Proteasome Activation to Combat Proteotoxicity
por: Jones, Corey L., et al.
Publicado: (2019)

Aneuploidy and proteotoxic stress in cancer
por: Donnelly, Neysan, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fbhao6tdsji708frk1uansmsil